These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23404816)

  • 41. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
    Grbic JT; Landesberg R; Lin SQ; Mesenbrink P; Reid IR; Leung PC; Casas N; Recknor CP; Hua Y; Delmas PD; Eriksen EF;
    J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
    Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
    Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dosing of zoledronic acid throughout the treatment continuum in breast cancer.
    Hadji P; Gnant M; Aapro M; Lipton A; Coleman R
    Crit Rev Oncol Hematol; 2011 Aug; 79(2):175-88. PubMed ID: 20846875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.
    Zaghloul MS; Boutrus R; El-Hossieny H; Kader YA; El-Attar I; Nazmy M
    Int J Clin Oncol; 2010 Aug; 15(4):382-9. PubMed ID: 20354750
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)].
    Ringe JD; Nitschmann S
    Internist (Berl); 2008 Apr; 49(4):502-4. PubMed ID: 18305914
    [No Abstract]   [Full Text] [Related]  

  • 47. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ; Lichinitser M; Tjulandin S; Garnero P; Bergström B
    Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
    Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
    Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
    Black DM; Reid IR; Boonen S; Bucci-Rechtweg C; Cauley JA; Cosman F; Cummings SR; Hue TF; Lippuner K; Lakatos P; Leung PC; Man Z; Martinez RL; Tan M; Ruzycky ME; Su G; Eastell R
    J Bone Miner Res; 2012 Feb; 27(2):243-54. PubMed ID: 22161728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
    Hines SL; Sloan JA; Atherton PJ; Perez EA; Dakhil SR; Johnson DB; Reddy PS; Dalton RJ; Mattar BI; Loprinzi CL
    Breast; 2010 Apr; 19(2):92-6. PubMed ID: 20079640
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Managing bone health with zoledronic acid: a review of randomized clinical study results.
    Hadji P
    Climacteric; 2011 Jun; 14(3):321-32. PubMed ID: 21182431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
    J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of Bisphosphonates in Breast Cancer Therapy.
    Goldvaser H; Amir E
    Curr Treat Options Oncol; 2019 Mar; 20(4):26. PubMed ID: 30874905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
    Hadji P; Coleman RE; Wilson C; Powles TJ; Clézardin P; Aapro M; Costa L; Body JJ; Markopoulos C; Santini D; Diel I; Di Leo A; Cameron D; Dodwell D; Smith I; Gnant M; Gray R; Harbeck N; Thurlimann B; Untch M; Cortes J; Martin M; Albert US; Conte PF; Ejlertsen B; Bergh J; Kaufmann M; Holen I
    Ann Oncol; 2016 Mar; 27(3):379-90. PubMed ID: 26681681
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
    Kim JE; Ahn JH; Jung KH; Kim SB; Kim HJ; Lee KS; Ro JS; Park YH; Ahn JS; Im YH; Im SA; Lee MH; Kim SY
    Breast Cancer Res Treat; 2011 Jan; 125(1):99-106. PubMed ID: 20922564
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis.
    Valachis A; Polyzos NP; Georgoulias V; Mavroudis D; Mauri D
    Gynecol Oncol; 2010 Apr; 117(1):139-45. PubMed ID: 20061004
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict?
    Gnant M
    Curr Oncol Rep; 2012 Feb; 14(1):35-43. PubMed ID: 22113793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
    Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
    Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.